Ignite Creation Date:
2024-05-05 @ 5:21 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00431678
Status:
COMPLETED
Last Update Posted:
2014-12-17
First Post:
2007-02-05
Brief Title:
Efficacy and Safety of Sequential IVPO Moxifloxacin in Comparison to IV Levofloxacin Plus IV Ceftriaxone Followed by PO Levofloxacin in the Treatment of Patients With Community-acquired Pneumonia
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
A Multinational Prospective Randomized Double-blind Study to Investigate the Efficacy and Safety of Sequential IntravenousOral Moxifloxacin in Comparison to Intravenous Levofloxacin Plus Intravenous Ceftriaxone Followed by Oral Levofloxacin in the Treatment of Patients With Severe Community-acquired Pneumonia
Status:
COMPLETED
Status Verified Date:
2014-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Sequential therapy with intravenous to oral moxifloxacin was tested at 69 study centres in 17 countries to determine if this treatment regimen is safe and effective in treating hospitalized adult patients with community-acquired pneumonia 748 patients were participated in the study over an 18 months period Individual patient involvement in the study was approximately 4-6 weeks Moxifloxacin was compared to a combination treatment regimen of high dose intravenous ceftriaxone plus high dose intravenous levofloxacin followed by high dose oral levofloxacin
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None